WO2008075216A1 - Indicator immobilization on assay devices - Google Patents
Indicator immobilization on assay devices Download PDFInfo
- Publication number
- WO2008075216A1 WO2008075216A1 PCT/IB2007/053962 IB2007053962W WO2008075216A1 WO 2008075216 A1 WO2008075216 A1 WO 2008075216A1 IB 2007053962 W IB2007053962 W IB 2007053962W WO 2008075216 A1 WO2008075216 A1 WO 2008075216A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lateral flow
- assay device
- indicator
- flow assay
- analyte
- Prior art date
Links
- PWMONIFQVMVBIC-UHFFFAOYSA-N [N-]=[NH+]c(cc1[N+]([O-])=O)ccc1F Chemical compound [N-]=[NH+]c(cc1[N+]([O-])=O)ccc1F PWMONIFQVMVBIC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
- G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/97—Test strip or test slide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/81—Tube, bottle, or dipstick
Definitions
- FIG. 10 illustrates a device 10 that includes a first zone 11 and a second zone 12.
- the first zone 11 is provided with polymer beads 13 (carrier) linked to streptavidin 14 (reporter) via a peptide linker 15 that is cleavable by a protease 16.
- the streptavidin 14 is released and passes to the second zone 12, which includes a biosensor membrane 17 that detects the presence of streptavidin through a change in the impedance of the membrane. (CoI. 5, II. 25-30).
- assays have been developed that are more 'user friendly'. For instance, assays have been developed that utilize indicators susceptible to a visible or detectable change upon action of an analyte. If the indicator undergoes a detectable change, e.g., a color change, the user may be confident that the analyte is present in the test sample.
- U.S. Patent No. 5,409,664 to Allen describes an assay device including an amine-functionalized bibulous assay strip including a signal producing system. Specifically, the reagent strip is impregnated with one or more members of the detectable signal reagent system. For example, when determining the amount of cholesterol in a sample, one could have cholesterol esterase in a first zone, cholesterol oxidase in a second zone, and horseradish peroxidase in a third zone.
- small molecular indicators usually work well in wet chemistry applications, in which a test sample is combined with a reagent-containing solution, but they are not equally suitable for use in dry chemistry applications due to, for instance, inability to maintain the dry small molecule indicators in an active state and at a specific location on a device during shipping and handling prior to use.
- dry chemistry applications are preferred due to there relative simplicity, speed of detection, and low cost.
- a lateral flow assay device for detecting the presence or quantity of an analyte in a test sample.
- the device comprises a chromatographic medium that defines a detection zone, wherein a crosslinked network is non-diffusively immobilized within the detection zone.
- the crosslinked network contains a small molecule indicator that is configured to undergo a detectable color change in the presence of the analyte.
- Fig. 1 is a perspective view of one embodiment of a flow-through assay device as described herein.
- analytes generally refers to a substance to be detected.
- analytes may include antigenic substances, haptens, antibodies, and combinations thereof.
- Analytes include, but are not limited to, toxins, organic compounds, proteins, peptides, microorganisms, amino acids, nucleic acids, hormones, steroids, vitamins, drugs (including those administered for therapeutic purposes as well as those administered for illicit purposes), drug intermediaries or byproducts, bacteria, virus particles and metabolites of or antibodies to any of the above substances.
- analytes include ferritin; creatinine kinase MIB (CK-MB); digoxin; phenytoin; phenobarbitol; carbamazepine; vancomycin; gentamycin; theophylline; valproic acid; quinidine; leutinizing hormone (LH); follicle stimulating hormone (FSH); estradiol, progesterone; C-reactive protein; lipocalins; IgE antibodies; vitamin B2 microglobulin; glycated hemoglobin (GIy.
- Hb Cortisol; digitoxin; bilirubin; urobilinogen; N-acetylprocainamide (NAPA); procainamide; antibodies to rubella, such as rubella-lgG and rubella IgM; antibodies to toxoplasmosis, such as toxoplasmosis IgG (Toxo-lgG) and toxoplasmosis IgM (Toxo-lgM); testosterone; salicylates; acetaminophen; hepatitis B virus surface antigen (HBsAg); antibodies to hepatitis B core antigen, such as anti-hepatitis B core antigen IgG and IgM (Anti-HBC); human immune deficiency virus 1 and 2 (HIV 1 and 2); human T-cell leukemia virus 1 and 2 (HTLV); hepatitis B e antigen (HBeAg); antibodies to hepatitis B e antigen (Anti-HBe); influenza virus; thyroid stimulating
- Drugs of abuse and controlled substances include, but are not intended to be limited to, amphetamine; methamphetamine; barbiturates, such as amobarbital, secobarbital, pentobarbital, phenobarbital, and barbital; benzodiazepines, such as librium and Valium; maynabinoids, such as hashish and marijuana; cocaine; fentanyl; LSD; methaqualone; opiates, such as heroin, morphine, codeine, hydromorphone, hydrocodone, methadone, oxycodone, oxymorphone and opium; phencyclidine; and propoxyhene.
- Other potential analytes may be described in U.S. Patent Nos. 6,436,651 to Everhart, et al. and 4,366,241 to Tom et al.
- test sample generally refers to a material suspected of containing the analyte.
- the test sample may be used directly as obtained from the source or following a pretreatment to modify the character of the sample.
- the test sample may be derived from any biological source, such as a physiological fluid, including, blood, interstitial fluid, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, raucous, synovial fluid, peritoneal fluid, vaginal fluid, amniotic fluid or the like.
- the test sample may be pretreated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like.
- Methods of treatment may involve filtration, precipitation, dilution, distillation, mixing, concentration, inactivation of interfering components, and the addition of reagents.
- physiological fluids other liquid samples may be used such as water, food products and the like for the performance of environmental or food production assays.
- a solid material suspected of containing the analyte may be used as the test sample. In some instances it may be beneficial to modify a solid test sample to form a liquid medium or to release the analyte.
- the present invention is directed to a method of securely immobilizing small molecule indicators onto a chromatographic medium of a lateral flow assay device.
- the indicator is a reactive chemical moiety that reacts with an analyte or with a reaction product that is generated through a process that requires participation of the analyte. Upon reaction with the analyte (or reaction product thereof), the indicator may exhibit a detectable color change.
- the indicator is typically a moiety of a small molecule in that the size of a small molecule is generally less than about 3000 Daltons (i.e., atomic mass units, one Dalton being equivalent to 1 ⁇ 2 the mass of a 12 C isotope) prior to any derivitizations, e.g., addition of reactive functionalities to the small molecule indicator.
- the small molecule indicator may be less than about 2000 Daltons, in some embodiments less than about 1000 Daltons, and in some embodiments, less than about 500 Daltons.
- the term 'indicator' may refer to either the reactive moiety capable of generating a detection signal upon reaction with an analyte or reaction product thereof or alternatively may refer to the small molecule that includes the indicator moiety.
- diazonium ion indicators are employed for the detection of various analytes, such as bilirubin and urobilinogen.
- the analyte may directly couple a diazonium ion to produce a product that differs in color from the starting materials.
- Diazonium ions may also be utilized in indirect detection of analytes, such as glucose and various proteins. That is, the analyte may initially react with a reagent, such as protein or an enzymatic substrate, to form a reaction product that in turn reacts with the diazonium ion to yield a detectable product.
- the diazonium ion may have the following generic formula:
- the diazonium ion may be zwitterionic in that the counterion of the diazonium moiety is covalently bound to the ring system.
- the ring system of the diazonium ion may be substituted or unsubstituted.
- the analyte or a reaction product thereof is capable of undergoing electrophilic attack by the diazonium ion.
- This reaction is often referred to as "coupling" and results in the formation of a product having a color different from that of the starting indicator reagent.
- this reaction induces either a shift of the absorption maxima towards the red end of the spectrum (“bathochromic shift”) or towards the blue end of the spectrum (“hypsochromic shift”).
- the type of absorption shift depends on the nature of the resulting azo molecule and whether it functions as an electron acceptor (oxidizing agent), in which a hypsochromic shift results, or whether it functions as an electron donor (reducing agent), in which a bathochromic shift results.
- the absorption shift provides a color difference that is detectable, either visually or through instrumentation, to indicate the presence of the analyte within the test sample.
- the diazonium ion prior to contact with an infected test sample, may be colorless or it may possess a certain color. However, after contacting the test sample and reacting with the analyte, or a reaction product formed in a process that requires participation of the analyte, an aromatic azo compound will form that exhibits a color that is different than the initial color of the diazonium ion.
- Diazonium ions may also be utilized to directly or indirectly detect the presence of an enzyme.
- an enzymatic substrate may be provided for detection of an enzyme (e.g., hydrolytic enzyme, such as leukocyte esterase).
- the provided substrate may be chemically acted upon (e.g., cleaved in the case of a protease) by the enzyme of interest to form a product.
- the substrate may be an aromatic ester that is catalytically hydrolyzed in the presence of leukocyte esterase to yield an aromatic compound.
- the aromatic esters may include, for instance, indoxyl esters having the following general formula:
- R may be substituted or unsubstituted, and may be an alkyl group, an alkyoxy group, a hydroxyalkyl group, an alkylene group, a fatty acid group, and so forth.
- the aromatic rings may also be substituted or unsubstituted. Specific examples include, for instance, indoxyl acetate, indoxyl butyrate, indoxyl laureate, indoxyl stearate, indoxyl ester of a N-blocked amino acid or peptide and thioindoxyl analogs thereof, and N-Tosyl-L-alanine 3-indoxyl ester.
- Such indoxyl esters are hydrolyzed by the leukocyte esterase to form a benzopyrrole, such as indoxyl, which has the following structure: H
- Lactate esters may also be used as substrates for enzyme detection.
- lactate esters may be used such as described in U.S. Patent Nos. 5,464,739 to Johnson, et al. and 5,663,044 to Noffsinqer, et al.. which are incorporated herein in their entirety by reference thereto for all purposes.
- Lactate esters are generally hydrolyzed by leukocyte esterase to provide a hydroxy-pyrrole compound.
- Other suitable ester substrates include thiazole esters, pyrrole esters, thiophene esters, naphthyl esters, phenoxyl esters, quinolinyl esters, such as described in U.S. Patent Nos.
- substrates for hydrolytic enzymes include, for instance, amides, peptides, ethers, or other chemical compounds having an enzymatically- hydrolyzable bond.
- Specific types of substrates may include proteins or glycoproteins, peptides, nucleic acids (e.g., DNA and RNA), carbohydrates, lipids, esters, derivatives thereof, and so forth.
- suitable substrates for peptidases and/or proteases may include peptides, proteins, and/or glycoproteins, such as casein (e.g., ⁇ -casein, azocasein, etc.), albumin (e.g., bovine serum albumin), hemoglobin, myoglobin, keratin, gelatin, insulin, proteoglymay, fibronectin, laminin, collagen, elastin, and so forth. Still other suitable substrates are described in U.S. Patent Nos.
- an aromatic compound may be formed through reaction of the analyte with the substrate that is capable of inducing a color change in the presence of a diazonium ion via a coupling reaction.
- diazonium salts include, without limitation, diazonium chlorides, diazonium acid sulphates, diazonium alkyl sulphates, diazonium fluoborates, diazonium benzenesulphonates, diazonium acid 1 ,5-naphthalenedisulphonates, and so forth.
- diazonium salts are 1-diazo-2-naphthol-4-sulfonate; 1-diazophenyl-3-carbonate; 4-diazo-3-hydroxy- 1-naphthylsulfonate (DNSA); 4-diazo-3-hydroxy-7-nitro-1-naphthylsulfonate
- NDNSA 4-diazo-3-hydroxy-1 ,7-naphthyldisulfonate; 2-methoxy-4-(N-morpholinyl) benzene diazonium chloride; 4-diazo-3-hydroxy-7-bromo-1-naphthylsulfonate; and 4-diazo-3-hydroxy-7-[1 ,oxopropyl]-1-naphthylsulfonate.
- One particularly desired diazonium salt is 5-chloro-2-methoxybenzenediazonium chloride, which has a yellow color and is classified under the name "Diazo Red RC" or "Fast Red RC.” More specifically, "Fast Red RC" has the following structure:
- Diazonium salts may also be utilized in a direct detection technique in which the diazonium ion directly binds to a particular analyte.
- the disclosed devices may be utilized in detection of analytes such as bilirubin and/or urobilinogen.
- Increased levels of bilirubin as well as the reduction products of bilirubin, e.g., urobilinogen, may be an indicator of several disease states including, for instance, malaria, sickle cell anemia, hepatitis B, hepatitis C, hepatotoxicity, alcoholism, cirrhosis, Gilbert's syndrome, gallstones, and maycers including pancreatic maycer, ductal carcinoma as well as metastatic carcinomas in general.
- a non-limiting listing of diazonium compounds suitable for use in the direct detection of bilirubin may include p-aminobenzenesulfonic acid, 2,6-dichlorobenzene diazonium tetrafluoroborate, 2-trifluoromethylbenzene diazonium, and so on.
- Diazonium ions that preferentially couple urobilinogen may include those having the following general structure
- X represents a stabilizing anion.
- a diazonium ion having the following general structure may be used for the preferential detection of urobilinogen:
- R1 through R7 are independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and X is a stabilizing anion.
- a non-limiting listing of diazonium compounds that may be utilized to preferentially directly couple urobilinogen may include 4-fluoro ⁇ 3-nitrobenzenediazonium salt, 4- methoxybenzene-diazonium-tetrafluoroborate, 3,3'-dimethoxybiphenyl-4,4'- diazonium salt, and the like.
- the present disclosure is not limited to diazonium-type small molecule indicators. Many other small molecule indicators are generally known to one of ordinary skill in the art and are encompassed in the present disclosure.
- Erhlich reagents are small molecule indicators that may be used in the detection of urobilinogen in a test sample.
- Erhlich reagents are p- aminobenzaldehyde molecules that may preferentially bind urobilinogen.
- Erhlich reagents for detection of urobilinogen may include, without limitation, dialkylaminobenzaldehydes such as dimethylaminobenzaldehyde and diethylaminobenzaldehyde.
- Benzidine-type indicators may undergo changes of color in the presence of peroxides, and thus are often utilized in detection of peroxidatively active substances such as, for example, glucose, occult blood, electrolytes, cholesterol, and a variety of proteins as are generally known in the art.
- Benzidine-type indicators have the following general structure: in which the R1 and R2 substituents may be independently selected from hydrogen, lower alkyl (i.e., alkyl having 1 to about 6 carbon atoms), lower alkyloxy (i.e., alkyloxy having 1 to about 6 carbon atoms), aryl or aryloxy.
- R1 and R2 may be independently substituted such as with hydroxy, halogen, cyano, and so on. Moreover, the R2 substituents may together form (CH 2 ) n in which n is 1 or 2.
- Typical compounds embraced by the term "benzidine-type" indicator include benzidine, o-tolidine, o-dianisidine, 3,3',5,5'-tetramethyIbenzidine (tetramethylbenzidine (TMB)), 3,3',5,5'-tetra(alkyl)benzidine, the various N- and N 1 - substituted benzidines and others.
- Phthaleins such as phenolphthalein (HIn), dibromothymolsulfonephthalein (bromothymol blue, BTB), octabromophenol- sulfophthalein (tetrabromophenol blue), octachlorophenol-sulfophthalein (tetrachlorophenol blue), as well as the mixed halogenated analogues, for example, 3', 3", 5' ,5"-tetrabromophenol-3,4,5,6-tetrachlorosulfophthaIein 3',3",5',5"- tetrachlorophenol-3,4,5,6-tetrabromosulfophthalein and 3 l ,3"-dichloro-5',5"- dibromophenol-3,4,5,6-tetrachlorosulfophthalein, are small molecule indicators that may be utilized, for example, in
- a crosslinked network containing the indicator is formed on a chromatographic medium of a lateral flow device.
- the crosslinked network may help durably secure the indicator, thereby allowing a user to more readily detect a change in its color during use.
- the crosslinked network may contain "intra-cross links” (i.e., covalent bonds between functional groups of a single molecule) and/or "inter-cross links” (i.e., covalent bonds between different molecules, e.g., between two indicator molecules or between an indicator molecule and the substrate surface).
- Crosslinking may be carried out via self crosslinking of the indicator and/or through the inclusion of a separate crosslinking agent.
- Suitable crosslinking agents may include polyglycidyl ethers, such as ethylene glycol diglycidyl ether and polyethylene glycol dicglycidyl ether; acrylamides; compounds containing one or more hydrolyzable groups, such as alkoxy groups (e.g., methoxy, ethoxy and propoxy); alkoxyalkoxy groups (e.g., methoxyethoxy, ethoxyethoxy and methoxypropoxy); acyloxy groups (e.g., acetoxy and octanoyloxy); ketoxime groups (e.g., dimethylketoxime, methylketoxime and methylethylketoxime); alkenyloxy groups (e.g., vinyloxy, isopropenyloxy, and 1- ethyl-2-methylvinyloxy); amino groups (e.g., dimethylamino, diethylamino and butylamino); aminoxy groups (e.
- any of a variety of different crosslinking mechanisms may be employed in the present invention, such as thermal initiation (e.g., condensation reactions, addition reactions, etc.), electromagnetic radiation, and so forth.
- electromagnetic radiation include, but are not limited to, electron beam radiation, natural and artificial radio isotopes (e.g., ⁇ , ⁇ , and ⁇ rays), x-rays, neutron beams, positively-charged beams, laser beams, ultraviolet, etc.
- Electron beam radiation for instance, involves the production of accelerated electrons by an electron beam device. Electron beam devices are generally well known in the art.
- an electron beam device may be used that is available from Energy Sciences, Inc., of Woburn, Massachusetts under the name "Microbeam LV.”
- Other examples of suitable electron beam devices are described in U.S. Patent Nos. 5,003,178 to Livesay; 5,962,995 to Avnerv; 6407492 to Avnerv. et al., which are incorporated herein in their entirety by reference thereto for all purposes.
- the wavelength ⁇ of the radiation may vary for different types of radiation of the electromagnetic radiation spectrum, such as from about 10 '14 meters to about 10 "5 meters.
- Electron beam radiation for instance, has a wavelength ⁇ of from about 10 "13 meters to about 10 "9 meters.
- the dosage may range from about 0.1 megarads (Mrads) to about 10 Mrads, and in some embodiments, from about 1 Mrads to about 5 Mrads.
- the source of electromagnetic radiation may be any radiation source known to those of ordinary skill in the art.
- an excimer lamp or a mercury lamp with a D-bulb may be used.
- Other specialty-doped lamps that emit radiation at a fairly narrow emission peak may be used with photoinitiators which have an equivalent absorption maximum.
- the V-bulb available from Fusion Systems, is another suitable lamp for use.
- specialty lamps having a specific emission band may be manufactured for use with one or more specific photoinitiators.
- thermal initiators may be employed in some embodiments that enhance the functionality of the selected crosslinking technique.
- Thermal initiators for instance, may be employed in certain embodiments, such as azo, peroxide, persulfate, and redox initiators.
- suitable thermal initiators include azo initiators such as 2,2 l -azobis(2,4-dimethylvaleronitrile), 2,2'- azobis(isobutyronitrile), 2,2'-azobis-2-methylbutyronitrile, 1 ,1'-azobis(1- cyclohexanecarbonitrile), 2,2'-azobis(methyl isobutyrate), 2,2'-azobis(2- amidinopropane) dihydrochloride, and 2,2'-azobis(4-methoxy-2,4- dimethylvaleronitrile); peroxide initiators such as benzoyl peroxide, acetyl peroxide, lauroyl peroxide, decanoyl peroxide, dicetyl peroxy
- Photoinitiators may likewise be employed, such as substituted acetophenones, such as benzyl dimethyl ketal and 1-hydroxycyclohexyl phenyl ketone; substituted alpha-ketols, such as 2-methyl-2- hydroxypropiophenone; benzoin ethers, such as benzoin methyl ether and benzoin isopropyl ether; substituted benzoin ethers, such as anisoin methyl ether; aromatic sulfonyl chlorides; photoactive oximes; and so forth (and mixtures thereof).
- Other suitable photoinitiators may be described in U.S. Patent No.
- an anchoring compound may be employed that links the indicator to the surface of the chromatographic medium and further improves the durability of the indicator on the lateral flow device.
- the anchoring compound is larger in size than the indicator, which improves its likelihood of remaining on the surface of the chromatographic medium during use.
- the anchoring compound may include a macromolecular compound, such as a polymer, oligomer, dendrimer, particle, etc.
- Polymeric anchoring compounds may be natural, synthetic, or combinations thereof.
- natural polymeric anchoring compounds include, for instance, polypeptides, proteins, DNA/RNA and polysaccharides (e.g., glucose-based polymers).
- synthetic polymeric anchoring compounds include, for instance, polyacrylic acid and polyvinyl alcohols.
- a polysaccharide anchoring compound is activated dextran.
- the anchoring compound may be a particle (sometimes referred to as a "bead" or "microbead”).
- Naturally occurring particles such as nuclei, mycoplasma, plasmids, plastids, mammalian cells (e.g., erythrocyte ghosts), unicellular microorganisms (e.g., bacteria), polysaccharides (e.g., agarose), etc.
- mammalian cells e.g., erythrocyte ghosts
- unicellular microorganisms e.g., bacteria
- polysaccharides e.g., agarose
- synthetic particles may also be utilized.
- latex microparticles are utilized.
- the particles are typically formed from polystyrene, butadiene styrenes, styreneacrylic-vinyl terpolymer, polymethylmethacrylate, polyethylmethacrylate, styrene-maleic anhydride copolymer, polyvinyl acetate, polyvinylpyridine, polydivinylbenzene, polybutyleneterephthalate, acrylonitrile, vinylchloride-acrylates, and so forth, or an aldehyde, carboxyl, amino, hydroxyl, or hydrazide derivative thereof.
- the shape of the particles may generally vary.
- the particles are spherical in shape.
- other shapes are also contemplated such as plates, rods, discs, bars, tubes, irregular shapes, etc.
- the size of the particles may also vary.
- the average size (e.g., diameter) of the particles may range from about 0.1 nanometers to about 1 ,000 microns, in some embodiments, from about 0.1 nanometers to about 100 microns, and in some embodiments, from about 1 nanometer to about 10 microns.
- the manner in which the anchoring compound is used to link the indicator and the chromatographic medium may vary. In one embodiment, for instance, the anchoring compound is attached to the indicator prior to application of both to the chromatographic medium.
- the anchoring compound may be bonded to the chromatographic medium prior to application of the indicator.
- the materials may be applied as separate components to the chromatographic medium and attachment reactions can take place in situ, optionally at the same time as the crosslinking of the network.
- the small molecule indicator may bind the anchoring compound
- the anchoring compound may bind the medium, and simultaneously, cross-linking reactions can take place between anchoring compounds, between indicators, or between the two.
- the cross-linked network thus formed may be physically held on the porous membrane of the chromatographic medium without the need for bonding between the porous membrane and the other components of the system.
- the crosslinked network portions of which may extend within and among the pores of the porous membrane, may be physically constrained on the membrane, even without specific bonds forming between the membrane and the components of the crosslinked network.
- attachment of the anchoring compound to a chromatographic medium as well as attachment of the anchoring compound to the indicator may be accomplished using carboxylic, amino, aldehyde, bromoacetyl, iodoacetyl, thiol, epoxy or other reactive functional groups, as well as residual free radicals and radical cations, through which a binding reaction may be accomplished and according to any suitable methods, e.g., thermal processes, photo-initiated processes, catalyzed reactions, and the like.
- a chromatographic medium may be amine- functionalized through contact with an amine-containing compound, such as 3- aminopropyltriethoxy silane, to increase the amine functionality of the surface and bind the anchoring compound to the surface via, e.g., aldehyde functionality of the anchoring compound.
- a surface functional group may also be incorporated on a particle-type anchoring compound as a reactive functionality, for instance when the surface of the particle contains a relatively high surface concentration of polar groups.
- the particle may be capable of direct bonding to a chromatographic medium and/or an indicator without the need for further modification.
- a charged anchoring compound such as a positively charged polyelectrolyte anchoring compound
- a negatively charged chromatographic medium such as negatively charged porous nitrocellulose membrane
- a negatively charged indicator such as a diazonium ion
- indicator density at a detection zone may be increased through binding of a plurality of indicators to a single anchoring compound molecule.
- a multifunctional dendrimeric anchoring compound such as 64-cascade:1 ,4-diaminobutane[4]:1- azabutylidene)60-propylamine (available as Astra mol (Am )64 dendrimer from DSM) can bind a plurality of indicators (e.g., N-(1-naphthyl)ethylenediamine dihydrochloride) in any suitable process as is generally known in the art.
- the indicator may be functionalized with a reactive moiety that may be used to bond a plurality of the indicators to an anchoring compound while protecting the indicator moiety of the small molecule indicator.
- a solution can be formed including about 11 mg N-(1- naphthyl)ethylenediamine dihydrochloride indicator and a suitable solvent (e.g., DMSO) including any additional reagents to facilitate bonding (e.g., about 18 mg sodium dicarbonate).
- a suitable solvent e.g., DMSO
- any additional reagents to facilitate bonding e.g., about 18 mg sodium dicarbonate.
- the indicator may then be functionalized in solution with a reactive moiety for bonding to the anchoring compound.
- a reactive moiety for bonding to the anchoring compound.
- about 9 mg N-hydroxysuccinimidyl-4-azidosalicylic acid (NHS-ASA, available from Pierce Biotech.) may be added to the solution and upon shaking (under dark) may functionalize the indicator with the photoreactive moiety.
- the anchoring compound can bind a plurality of the indicators.
- the solution containing the anchoring compound/indicator complex thus formed may then be further treated as desired and applied to a chromatographic medium.
- the solution thus formed may be dialyzed in acidic water using a membrane (e.g., a 3,500 cut-off membrane from Pierce Biotech).
- the dialyzed solution may then be applied to a chromatographic medium (e.g., a nitrocellulose membrane) and crosslinked to form a detection zone, for instance a detection zone for nitrite.
- crosslink reactions may occur to form the crosslinked network.
- crosslink reactions may occur between two of the chromatographic medium surface, the anchoring compound, and the indicator as well as between any two of the same components as inter-crosslinks (e.g., between two anchoring compounds or between two small molecule indicators) or among a single component as intra- crosslinks (e.g., between two functional moieties on a single polymeric anchoring compound).
- a multi-functional anchoring compound may crosslink the indicator, may crosslink adjacent anchoring compounds (inter-crosslinking), and/or may crosslink within itself (intra-crosslinking).
- multi-functional indicators may crosslink with each other and/or with adjacent anchoring compounds to form crosslinks within the crosslinked indicator network.
- a multi-functional anchoring compound and an indicator may be applied as a mixture to the detection zone, optionally with a suitable crosslinking agent and/or a crosslink initiator.
- a crosslinked network may be formed that includes the securely immobilized indicator.
- the anchoring compound may include a polycarboxylic acid or cyclic anhydride groups, either of which may form ester bonds in the presence of suitable pH and temperature conditions between both a reactive moiety of a small molecule indicator (e.g., a cyclodextrin moiety) and a polysaccharide chromatographic medium (e.g., a cellulose).
- the anchoring compound may also be a biological macromolecule, such as a protein or a polynucleic acid. Proteins, such as antibodies and albumin, are known to be capable of being immobilized on chromatographic mediums such as nitrocellulose. Indicators may be attached covalently to such biological anchoring compounds via existing or altered chemistries.
- the indicator may be bound to an albumin anchoring compound via the lysine groups or carboxylic groups of the protein. Such attachment chemistry is well known in the art.
- methods of covalently binding a base such as may be present in a polynucleotide anchoring compound with a small molecule indicator including functional reactivity are generally known in the art.
- the anchoring compound may then be crosslinked with inter- and intra-crosslinks to form the crosslinked network containing the indicator.
- the indicator moiety of the small molecule indicator may be protected during the network formation processes.
- the anchoring compound and/or the chromatographic medium may include reactive functionality that does not react with the indicator moiety during formation.
- the other system components may include reactive functionality that preferentially reacts under the network formation conditions with a moiety of the small molecule indicator other than the indicator itself. Accordingly, reaction conditions may then be controlled so as to preferentially form the desired bonds while protecting the indicator moiety.
- the small molecule indicator may include a plurality of similar reactive sites, for instance in the case of a polyamine diazonium compound the small molecule indicator may include a plurality of reactive amines that may be utilized to bind the small molecule indicator to an anchoring compound. Upon reaction of the anchoring compound with the indicator, a portion of the amine groups may be used to bind the indicator to the anchoring compound and optionally in cross-linking the network, and the reactivity of the indicator may be maintained.
- a membrane-based flow-through assay device 20 is illustrated.
- the device 20 contains a chromatographic medium 23 optionally supported by a rigid material 21.
- the chromatographic medium 23 may be formed from any of a variety of materials through which the test sample is capable of passing.
- the materials used to form the medium may include, but are not limited to, natural, synthetic, or naturally occurring materials that are synthetically modified, such as polysaccharides (e.g., cellulose materials such as paper and cellulose derivatives, such as cellulose acetate and nitrocellulose); silica; inorganic materials, such as deactivated alumina, diatomaceous earth, MgSO 4 , or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, with polymers such as vinyl chloride, vinyl chloride-propylene copolymer, and vinyl chloride-vinyl acetate copolymer; cloth, both naturally occurring (e.g., cotton) and synthetic (e.g., nylon or rayon); porous gels, such as silica gel, agarose, dextran, and gelatin; polymeric films, such as polyacrylamide; and the like.
- polysaccharides e.g., cellulose materials such as paper and cellulose derivatives, such as cellulose acetate and
- the chromatographic medium is formed from nitrocellulose and/or polyester sulfone materials.
- nitrocellulose refers to nitric acid esters of cellulose, which may be nitrocellulose alone, or a mixed ester of nitric acid and other acids, such as aliphatic carboxylic acids having from 1 to 7 carbon atoms.
- the chromatographic medium 23 defines a detection zone 31 within which is contained a crosslinked network containing the indicator (not shown).
- the crosslinked network is affixed to the surface of the chromatographic medium 23 so that it does not diffuse through the matrix of the chromatographic medium 23.
- the detection zone 31 may generally provide any number of distinct detection regions so that, in one embodiment, a user may determine the concentration of a particular analyte within a test sample.
- Each region may include a crosslinked network that may contain the same indicator or may contain different indicators for capturing multiple analytes.
- the detection zone 31 may include two or more distinct detection regions (e.g., lines, dots, etc.).
- the detection regions may be disposed as discrete layers that may be in the form of lines in a direction that is substantially perpendicular to the flow of the test sample through the assay device 20. Likewise, in some embodiments, the detection regions may be disposed in the form of lines in a direction that is substantially parallel to the flow of the test sample through the assay device.
- the device 20 may also contain an absorbent pad 28.
- the absorbent pad 28 generally receives fluid that has migrated through the entire chromatographic medium 23. As is well known in the art, the absorbent pad 28 may assist in promoting capillary action and fluid flow through the membrane 23.
- a user may directly apply the test sample to an application pad 24 of the chromatographic medium 23 that is in fluid communication with the chromatographic medium 23.
- Some suitable materials that may be used to form the application pad 24 include, but are not limited to, nitrocellulose, cellulose, porous polyethylene pads, and glass fiber filter paper.
- the application pad 24 may also contain one or more assay pretreatment reagents, either diffusively or non-diffusively attached thereto.
- the test sample travels from the application pad 24 to a conjugate pad 22 that is placed in communication with one end of the application pad 24.
- the conjugate pad 22 is formed from a material through which the test sample is capable of passing.
- the conjugate pad 22 is formed from glass fibers. Although only one conjugate pad 22 is shown, it should be understood that other conjugate pads may also be used.
- various reagents may be immobilized at the conjugate pad 22.
- a test sample including an analyte such as glucose may travel to the conjugate pad 22, where the analyte mixes with reagents including glucose oxidase, peroxidase, and a suitable buffer.
- the glucose oxidase catalyzes the oxidation of glucose, yielding the peroxidase hydrogen peroxide.
- the materials may migrate from the conjugate pad 22 to a detection zone 31 within which is a crosslinked network that includes an indicator, such as a benzidine-type indicator (e.g., TMB).
- an indicator such as a benzidine-type indicator (e.g., TMB).
- the hydrogen peroxide causes a color change in the indicator.
- the specific location of any or all of the reagents may be optimized with respect to the location of the detection zone. For instance, in some embodiments, it may be preferred to include a buffer diffusively immobilized within the detection zone 31.
- analyte concentration increases in a test sample, more analyte (or a reaction product thereof) may react with the indicator within the detection zone 31.
- the increased quantity of reaction at the detection zone 31 results in an increase in signal intensity.
- the presence or concentration of the analyte may be readily determined.
- the amount of analyte is directly proportional to the signal intensity at the detection zone 31 , h .
- the signal intensity h may be plotted versus the analyte concentration for a range of known concentrations to generate an intensity curve. To determine the quantity of analyte in an unknown test sample, the signal intensity may then be converted to analyte concentration according to the intensity curve.
- one or more distinct regions of the detection zone 31 may exhibit the above-described relationship between signal intensity and analyte concentration; however, each and every distinct region need not exhibit such a relationship.
- only one of multiple distinct regions may exhibit a signal intensity that is directly proportional to the concentration of the analyte.
- the signal intensity of other distinct regions, such as those used to reduce false positives, may otherwise remain constant, or exhibit an increase and/or decrease in signal intensity. So long as at least one distinct region of the detection zone 31 satisfies the direct relationship, the signal intensity exhibited by the detection zone 31 is considered directly proportional to the enzyme concentration.
- the assay device 20 may also include a control zone 32.
- Control zone 32 may be utilized to determine if the device is working properly.
- Control zone 32 may be provided with a receptive material that is capable of binding to reagents that may be diffusively dispersed on the chromatographic medium 23 upstream of the control zone 32. More specifically, detectable reagents may be employed that flow through the chromatographic medium 23 upon contact with a sufficient volume of the test sample. These detectable reagents may then be observed, either visually or with an instrument, within the control zone 32.
- the control reagents generally contain a detectable substance, such as luminescent compounds (e.g., fluorescent, phosphorescent, etc.); radioactive compounds; visual compounds (e.g., colored dye or metallic substance, such as gold); liposomes or other vesicles containing signal-producing substances; enzymes and/or substrates, and so forth.
- a detectable substance such as luminescent compounds (e.g., fluorescent, phosphorescent, etc.); radioactive compounds; visual compounds (e.g., colored dye or metallic substance, such as gold); liposomes or other vesicles containing signal-producing substances; enzymes and/or substrates, and so forth.
- a detectable substance such as luminescent compounds (e.g., fluorescent, phosphorescent, etc.); radioactive compounds; visual compounds (e.g., colored dye or metallic substance, such as gold); liposomes or other vesicles containing signal-producing substances; enzymes and/or substrates, and so forth.
- control zone 32 may vary based on the nature of the test being performed.
- the control zone 32 is defined by the chromatographic medium 23 and positioned downstream from the detection zone 31.
- the control zone 32 may contain a material that is non- diffusively immobilized and forms a chemical and/or physical bond with the detectable reagents.
- the binders may contain a biological receptive material.
- the receptive material may be a biological receptive material.
- biological receptive materials are well known in the art and may include, but are not limited to, antigens, haptens, antibodies, protein A or G, avidin, streptavidin, secondary antibodies, and complexes thereof.
- these biological receptive materials are capable of binding to a specific binding member (e.g., antibody) present on the detectable reagents.
- a specific binding member e.g., antibody
- various non-biological materials may be utilized for the detectable reagent receptive material.
- the receptive material may include a polyelectrolyte that may bind to the detectable reagents.
- polyelectrolytic binding systems are described, for instance, in U.S. Patent App. Publication No. 2003/0124739 to Song, et al., which is incorporated herein in it entirety by reference thereto for all purposes.
- the control zone 32 may simply be defined by a region of the absorbent material 28 to which the detectable reagents flow after traversing through the chromatographic medium 23.
- the application of a sufficient volume of the test sample to the device 20 will cause a signal to form within the control zone 32, whether or not the analyte is present.
- a control zone is that the user is informed that a sufficient volume of test sample has been added without requiring careful measurement or calculation. This provides the ability to use the lateral flow device 20 without the need for externally controlling the reaction time, test sample volume, etc.
- the quenching zone 35 is configured to remove compounds from the test sample that would otherwise interfere with the accuracy of the detection system.
- contaminants within the test sample e.g., phenolics, bilirubin, urobilinogen, etc.
- the quenching zone 35 may contain a quenching agent, such as a diazonium ion, that is capable of reacting with the reaction contaminants.
- the quenching agent may be the same or different than the indicator used within the detection zone 31.
- the quenching agent may non-diffusively immobilized within the quenching zone 35 in the manner described above so that it does not flow through the medium 23 and interfere with testing.
- the location of the quenching zone 35 may vary, but is typically positioned upstream from the detection zone 31 and the location at which the sample is applied to avoid interference with detection.
- the quenching zone 35 is positioned between the sample application zone 24 and the reagent zone 22.
- the lateral flow device 20 may also include other optional zones.
- the lateral flow device 20 may include an accelerator zone (not shown) in which is contained an accelerator for an enzyme-catalyzed substrate reaction.
- the accelerator is diffusively immobilized within the accelerator zone in the manner described above so that it may flow through the medium 23 upon contact with the test sample.
- the location of the accelerator zone may generally vary, so long as it positioned upstream from the detection zone 31.
- the accelerator zone may be positioned at a location (e.g., sample application zone 24) that is upstream from the reagent zone 22. Due to the separation provided between the substrate provided in the reagent zone 22 and accelerator, the likelihood of any premature reaction therebetween is thus reduced. It should be understood, however, that the accelerator may nevertheless be combined with a substrate in some applications.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Plasma & Fusion (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009540899A JP5296703B2 (en) | 2006-12-15 | 2007-09-28 | Indicator fixed on analyzer |
KR1020097012200A KR101481189B1 (en) | 2006-12-15 | 2007-09-28 | Indicator immobilization on assay devices |
CN2007800463124A CN101558301B (en) | 2006-12-15 | 2007-09-28 | Indicator immobilization on assay devices |
CA002670526A CA2670526A1 (en) | 2006-12-15 | 2007-09-28 | Indicator immobilization on assay devices |
EP07826591.5A EP2092332B1 (en) | 2006-12-15 | 2007-09-28 | Indicator immobilization on assay devices |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/640,100 | 2006-12-15 | ||
US11/640,100 US7935538B2 (en) | 2006-12-15 | 2006-12-15 | Indicator immobilization on assay devices |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008075216A1 true WO2008075216A1 (en) | 2008-06-26 |
Family
ID=39247279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/053962 WO2008075216A1 (en) | 2006-12-15 | 2007-09-28 | Indicator immobilization on assay devices |
Country Status (7)
Country | Link |
---|---|
US (1) | US7935538B2 (en) |
EP (1) | EP2092332B1 (en) |
JP (1) | JP5296703B2 (en) |
KR (1) | KR101481189B1 (en) |
CN (1) | CN101558301B (en) |
CA (1) | CA2670526A1 (en) |
WO (1) | WO2008075216A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2217922A1 (en) * | 2007-12-14 | 2010-08-18 | Kimberly-Clark Worldwide, Inc. | Urine volume hydration test devices |
US9591290B2 (en) | 2014-06-10 | 2017-03-07 | Bitanimate, Inc. | Stereoscopic video generation |
US9733242B2 (en) | 2012-10-07 | 2017-08-15 | Sevident, Inc. | Devices for capturing analyte |
US9910040B2 (en) | 2012-07-09 | 2018-03-06 | Sevident, Inc. | Molecular nets comprising capture agents and linking agents |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9103796B2 (en) | 2007-12-14 | 2015-08-11 | Kimberly-Clark Worldwide, Inc. | Multi-layered devices for analyte detection |
US20100159611A1 (en) * | 2008-12-18 | 2010-06-24 | Xuedong Song | Hydration/dehydration sensor |
CN107462707A (en) * | 2009-11-24 | 2017-12-12 | 赛维登特公司 | For testing and analyzing the device of thing |
US8920857B2 (en) * | 2010-12-22 | 2014-12-30 | Michael T. Abramson | System and method for detection of a contaminated beverage |
US8815532B2 (en) | 2011-06-07 | 2014-08-26 | Diagnostic Innovations, Llc | Color-producing diagnostic systems, reagents and methods |
CA2846247A1 (en) | 2011-09-16 | 2013-03-21 | Credo Biomedical Pte Ltd | Molecular diagnostic assay device and method of use |
EP2803995B1 (en) * | 2012-01-11 | 2022-09-07 | Daicel Corporation | Chromatographic medium |
GB201321430D0 (en) * | 2013-12-04 | 2014-01-15 | Spd Swiss Prec Diagnostics Gmbh | Assay device |
KR101593114B1 (en) * | 2014-04-09 | 2016-02-11 | 이성동 | Biosensor |
FR3034686B1 (en) | 2015-04-13 | 2019-06-14 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | METHOD FOR GRAFTING A COLORED INDICATOR ON A SOLID MEDIUM AND KIT FOR IMPLEMENTING IT |
CN105699370B (en) * | 2016-01-20 | 2018-09-18 | 江西华清博恩生物科技有限公司 | Amniotic fluid detects director composition, its preparation and corresponding amniotic fluid detection protection pad |
US11104933B1 (en) | 2016-03-22 | 2021-08-31 | Cleu Diagnostics, Llc | Compositions and methods for determining the presence of active leukocyte cells using an electrochemical assay |
GB201614053D0 (en) * | 2016-08-17 | 2016-09-28 | Microarray Ltd | Determining the condition of a wound |
JP6635345B2 (en) * | 2017-02-14 | 2020-01-22 | 学校法人慶應義塾 | Method for detecting biomarker in urine and kit for use in the method |
KR20190140034A (en) * | 2017-05-04 | 2019-12-18 | 지멘스 헬쓰케어 다이아그노스틱스 인크. | Apparatus and method for minimizing hook effect interference in immunoassay |
CN115210557A (en) * | 2019-10-21 | 2022-10-18 | 韦里特克美国有限公司 | Fentanyl analogue detection method and kit thereof |
CN112161972B (en) * | 2020-08-14 | 2021-04-20 | 大连理工大学 | Detection test paper group for rapidly and quantitatively detecting aromatic primary amine content in acidic solution in grading manner and application thereof |
US20230062903A1 (en) * | 2021-08-11 | 2023-03-02 | Senzo Health Limited | High sensitivity analyte network detection flow assays and related methods |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US5571684A (en) | 1994-11-07 | 1996-11-05 | Litmus Concepts, Inc. | Assay for proline iminopeptidase and other hydrolytic activities |
WO2001086302A1 (en) * | 2000-05-05 | 2001-11-15 | Pharmacia Diagnostics Ab | Assay device with timer function |
US6436651B1 (en) | 1997-12-16 | 2002-08-20 | Kimberly-Clark Worldwide, Inc. | Optical diffraction biosensor |
US6486227B2 (en) | 2000-06-19 | 2002-11-26 | Kimberly-Clark Worldwide, Inc. | Zinc-complex photoinitiators and applications therefor |
WO2003058246A1 (en) * | 2001-12-24 | 2003-07-17 | Kimberly-Clark Worldwide, Inc. | Flow-through assay with an internal calibration system using polyelectrolyte |
US6780896B2 (en) | 2002-12-20 | 2004-08-24 | Kimberly-Clark Worldwide, Inc. | Stabilized photoinitiators and applications thereof |
WO2005086744A2 (en) * | 2004-03-08 | 2005-09-22 | Metrika, Inc. | Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays |
WO2007027198A1 (en) * | 2005-08-31 | 2007-03-08 | Kimberly-Clark Worldwide, Inc. | Nitrite detection technique |
WO2007027234A2 (en) * | 2005-08-31 | 2007-03-08 | Kimberly-Clark Worldwide, Inc. | Enzyme detection technique |
WO2007027353A2 (en) * | 2005-08-31 | 2007-03-08 | Kimberly-Clark Worldwide, Inc. | Detection of proteases secreted from pathogenic microorganisms |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622871A (en) | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
US3951748A (en) | 1974-11-11 | 1976-04-20 | Medical Products, Inc. | Sensitized matrix for detection of disease |
EP0111762B1 (en) | 1980-06-20 | 1987-11-19 | Unilever Plc | Processes and apparatus for carrying out specific binding assays |
JPS57501234A (en) | 1980-08-25 | 1982-07-15 | ||
US4483920A (en) | 1982-05-17 | 1984-11-20 | Hahnemann University | Immobilization of message RNA directly from cells onto filter material |
JPH0665987B2 (en) * | 1982-11-19 | 1994-08-24 | 富士写真フイルム株式会社 | Analysis element |
US4895809A (en) | 1984-01-09 | 1990-01-23 | Varian Associates, Inc. | Immobilized antigen-antibody displacement process |
GB8406752D0 (en) | 1984-03-15 | 1984-04-18 | Unilever Plc | Chemical and clinical tests |
US4743560A (en) | 1984-03-26 | 1988-05-10 | Becton Dickinson And Company | Solid phase assay |
DE3413077A1 (en) | 1984-04-06 | 1985-10-17 | Miles Laboratories, Inc., Elkhart, Ind. | CHROMOGENEIC AMINO ACID AND PEPTIDESTERS, METHOD FOR THE PRODUCTION THEREOF, USE OF THESE COMPOUNDS IN ANALYZING METHODS AND MEANS FOR DETECTING ESTEROLYTIC AND / OR PROTEOLYTIC ENZYMES |
US4657855A (en) | 1984-04-06 | 1987-04-14 | Miles Laboratories, Inc. | Composition and test device for determining the presence of leukocytes, esterase and protease in a test sample |
US4637979A (en) | 1984-04-06 | 1987-01-20 | Miles Laboratories, Inc. | Composition and test device for determining the presence of leukocytes containing a zwitterion coupling agent |
DE3413078A1 (en) | 1984-04-06 | 1985-10-24 | Miles Laboratories, Inc., Elkhart, Ind. | CHROMOGENEIC AMINO ACID AND PEPTIDESTERS, METHOD FOR THE PRODUCTION THEREOF, USE OF THESE COMPOUNDS IN ANALYZING METHODS AND MEANS FOR DETECTING ESTEROLYTIC AND / OR PROTEOLYTIC ENZYMES |
GB2161165A (en) | 1984-06-12 | 1986-01-08 | Cambridge Patent Dev | Secondary antibodies |
US4806311A (en) | 1985-08-28 | 1989-02-21 | Miles Inc. | Multizone analytical element having labeled reagent concentration zone |
TW203120B (en) | 1985-10-04 | 1993-04-01 | Abbott Lab | |
US5500350A (en) | 1985-10-30 | 1996-03-19 | Celltech Limited | Binding assay device |
GB8528720D0 (en) | 1985-11-21 | 1985-12-24 | Williams J | Disposable nappies |
US5178831A (en) * | 1986-10-08 | 1993-01-12 | Dai Nippon Insatsu Kab Ushiki Kaisha | Device for testing body fluids |
US4835099A (en) | 1986-11-20 | 1989-05-30 | Becton, Dickinson And Company | Signal enhancement in immunoassay by modulation of enzymatic catalysis |
US4954435A (en) | 1987-01-12 | 1990-09-04 | Becton, Dickinson And Company | Indirect colorimetric detection of an analyte in a sample using ratio of light signals |
USRE38430E1 (en) | 1987-03-27 | 2004-02-17 | Becton, Dickinson And Company | Solid phase chromatographic immunoassay |
CA1303983C (en) | 1987-03-27 | 1992-06-23 | Robert W. Rosenstein | Solid phase assay |
JPH0684970B2 (en) | 1987-03-31 | 1994-10-26 | 株式会社京都医科学研究所 | Method of detecting occult blood in feces |
JPH0746107B2 (en) | 1987-04-27 | 1995-05-17 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Test method |
US4904583A (en) | 1987-05-26 | 1990-02-27 | Becton, Dickinson And Company | Cascade immunoassay by multiple binding reactions |
US4943522A (en) | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US4956302A (en) | 1987-09-11 | 1990-09-11 | Abbott Laboratories | Lateral flow chromatographic binding assay device |
US5571667A (en) | 1987-10-01 | 1996-11-05 | Chu; Albert E. | Elongated membrane flow-through diagnostic device and method |
US5073340A (en) | 1987-10-08 | 1991-12-17 | Becton, Dickinson And Company | Depositing a binder on a solid support |
US4978625A (en) | 1987-10-19 | 1990-12-18 | Becton, Dickinson And Company | Fluorescence immunoassay using water insoluble dyes |
US5275785A (en) | 1987-10-30 | 1994-01-04 | Unilever Patent Holdings B.V. | Test device for detecting an analyte in a liquid sample |
US5670381A (en) | 1988-01-29 | 1997-09-23 | Abbott Laboratories | Devices for performing ion-capture binding assays |
JPH01206257A (en) * | 1988-02-12 | 1989-08-18 | Kokusai Shiyaku Kk | Reagent and instrument for detecting urobilinogen |
US5573919A (en) | 1988-06-02 | 1996-11-12 | Carter-Wallace | Assay using an absorbent material |
AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
US5252459A (en) | 1988-09-23 | 1993-10-12 | Abbott Laboratories | Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles |
US5003178A (en) | 1988-11-14 | 1991-03-26 | Electron Vision Corporation | Large-area uniform electron source |
US5208143A (en) | 1988-11-17 | 1993-05-04 | Becton, Dickinson And Company | Immunoassay on a preblocked solid surface |
MY104234A (en) | 1988-11-17 | 1994-02-28 | Becton Dickinson Co | Immunoassay on a preblocked solid surface |
US6352862B1 (en) | 1989-02-17 | 2002-03-05 | Unilever Patent Holdings B.V. | Analytical test device for imuno assays and methods of using same |
US5185127A (en) | 1989-09-21 | 1993-02-09 | Becton, Dickinson And Company | Test device including flow control means |
US5075078A (en) | 1989-10-05 | 1991-12-24 | Abbott Laboratories | Self-performing immunochromatographic device |
US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
US6274324B1 (en) | 1989-12-01 | 2001-08-14 | Unilever Patent Holdings B.V. | Specific binding reagent comprising a variable domain protein linked to a support or tracer |
US5252496A (en) | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
US5238652A (en) | 1990-06-20 | 1993-08-24 | Drug Screening Systems, Inc. | Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques |
US5686315A (en) | 1991-06-14 | 1997-11-11 | Quidel Corporation | Assay device for one step detection of analyte |
US5428690A (en) | 1991-09-23 | 1995-06-27 | Becton Dickinson And Company | Method and apparatus for automated assay of biological specimens |
WO1993018398A1 (en) | 1992-03-10 | 1993-09-16 | Quidel Corporation | Red blood cell separation means for specific binding assays |
DE4217474A1 (en) | 1992-05-27 | 1993-12-02 | Boehringer Mannheim Gmbh | Method and means for determining an analyte |
US5395754A (en) | 1992-07-31 | 1995-03-07 | Hybritech Incorporated | Membrane-based immunoassay method |
AU4798793A (en) * | 1992-08-10 | 1994-03-03 | Monolithic System Technology, Inc. | Fault-tolerant, high-speed bus system and bus interface for wafer-scale integration |
US5354692A (en) | 1992-09-08 | 1994-10-11 | Pacific Biotech, Inc. | Analyte detection device including a hydrophobic barrier for improved fluid flow |
US5807752A (en) | 1992-09-11 | 1998-09-15 | Boehringer Mannheim Corporation | Assay using an unblocked solid phase with immobilized analyte binding partner |
US5571864A (en) * | 1993-03-23 | 1996-11-05 | Regents Of The University Of Minnesota | Miscible polyolefin blends with modifying polyolefin having matching segment lengths |
US5409664A (en) | 1993-09-28 | 1995-04-25 | Chemtrak, Inc. | Laminated assay device |
US5547833A (en) | 1994-01-04 | 1996-08-20 | Intracel Corporation | Radial flow assay, delivering member, test kit, and methods |
DE4403437A1 (en) | 1994-02-04 | 1995-08-10 | Karl Heinz Stawski | Disposable nappy has dampness indicator |
US5658747A (en) | 1994-05-10 | 1997-08-19 | Biocontrol System, Inc. | Compositions and methods for control of reactivity between diagnostic reagents and microorganisms |
US5501836A (en) * | 1994-07-11 | 1996-03-26 | Hewlett Packard Company | Entrapped non-enzymatic macromolecules for chemical sensing |
US5464739A (en) | 1994-08-22 | 1995-11-07 | Bayer Corporation | Composition method for determining the presence of leukocyte cells, esterase or protease in a test sample |
GB9419267D0 (en) | 1994-09-23 | 1994-11-09 | Unilever Plc | Assay devices |
CA2161574A1 (en) | 1994-11-15 | 1996-05-16 | James Noffsinger | Methodology for colorimetrically determining the concentration of white blood cells in a biological fluid |
DE69530315T2 (en) | 1994-11-24 | 2004-02-12 | Inverness Medical Switzerland Gmbh | RECOVERY AND USE OF SPECIFIC BINDING REAGENTS |
US5567596A (en) | 1994-12-29 | 1996-10-22 | Research Foundation Of State University Of New York | Rapid assay of activators and inhibitors of clotting |
US5569608A (en) | 1995-01-30 | 1996-10-29 | Bayer Corporation | Quantitative detection of analytes on immunochromatographic strips |
GB9505425D0 (en) | 1995-03-17 | 1995-05-03 | Unilever Plc | Assay devices |
US5712172A (en) | 1995-05-18 | 1998-01-27 | Wyntek Diagnostics, Inc. | One step immunochromatographic device and method of use |
US5788863A (en) | 1995-12-13 | 1998-08-04 | Becton Dickinson And Company | Apparatus and method for conducting an assay using reverse flow through a membrane |
US5741662A (en) | 1995-12-18 | 1998-04-21 | Quidel Corporation | Direct stain specific binding assays for microorganisms |
US5945281A (en) | 1996-02-02 | 1999-08-31 | Becton, Dickinson And Company | Method and apparatus for determining an analyte from a sample fluid |
CA2245664A1 (en) | 1996-02-08 | 1997-08-14 | Australian Membrane And Biotechnology Research Institute | Enzyme detection biosensors |
US5874216A (en) | 1996-02-23 | 1999-02-23 | Ensys Environmental Products, Inc. | Indirect label assay device for detecting small molecules and method of use thereof |
JP2000503773A (en) | 1996-05-23 | 2000-03-28 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Improved specific binding assays |
KR980010425A (en) | 1996-07-30 | 1998-04-30 | 안홍원 | Compositions and measuring instruments for the detection of urine leukocytes and proteolytic enzymes |
US5798273A (en) | 1996-09-25 | 1998-08-25 | Becton Dickinson And Company | Direct read lateral flow assay for small analytes |
US5998221A (en) | 1996-09-25 | 1999-12-07 | Becton, Dickinson And Company | Non-instrumented assay with quantitative and qualitative results |
US6194220B1 (en) | 1996-09-25 | 2001-02-27 | Becton, Dickinson And Company | Non-instrumented assay with quantitative and qualitative results |
EP0833145B1 (en) | 1996-09-27 | 2003-01-29 | Inverness Medical Switzerland GmbH | Test kit and devices |
EP0833157B1 (en) | 1996-09-27 | 2002-11-20 | Inverness Medical Switzerland GmbH | Assay reagents and devices |
EP0833158B1 (en) | 1996-09-27 | 2001-11-28 | Unilever Plc | Manufacture of test strips |
US6979576B1 (en) | 1997-07-25 | 2005-12-27 | Shu-Ching Cheng | Methods of use of one step immunochromatographic device for Streptococcus A antigen |
US5962995A (en) | 1997-01-02 | 1999-10-05 | Applied Advanced Technologies, Inc. | Electron beam accelerator |
US6407492B1 (en) | 1997-01-02 | 2002-06-18 | Advanced Electron Beams, Inc. | Electron beam accelerator |
US6057165A (en) | 1997-02-07 | 2000-05-02 | Becton, Dickinson And Company | Quality control procedure for membrane flow-through diagnostic assay devices |
GB2322192B (en) | 1997-02-14 | 2001-01-31 | Unilever Plc | Assay devices |
US5989924A (en) | 1997-09-30 | 1999-11-23 | Becton, Dickinson And Company | Device for determining an analyte in a sample |
US6077669A (en) | 1997-11-04 | 2000-06-20 | Becton Dickinson And Company | Kit and method for fluorescence based detection assay |
US6017723A (en) | 1998-03-27 | 2000-01-25 | Long Island Jewish Medical Center | Method for isolating inhibitors of protease activity |
GB9807134D0 (en) | 1998-04-02 | 1998-06-03 | Unilever Plc | Test methods devices and test kits |
ES2143434B1 (en) | 1998-09-16 | 2000-12-16 | Cerrato Paula Jimenez | DIAPER WITH INDICATORS SENSITIVE TO THE STATE OF URINE THAT IMPREGATES IT VISUALIZABLE FROM THE OUTSIDE. |
US6140136A (en) | 1998-09-18 | 2000-10-31 | Syntron Bioresearch, Inc. | Analytical test device and method of use |
AUPP713498A0 (en) * | 1998-11-17 | 1998-12-10 | Chandler, Howard Milne | A method of detecting blood |
DE19927783A1 (en) | 1999-06-18 | 2000-12-21 | Roche Diagnostics Gmbh | Element for determining an analyte in a liquid, corresponding determination method using the element and kit for determining an analyte |
JP2001021560A (en) * | 1999-07-07 | 2001-01-26 | Nitto Denko Corp | Immunity chromatography |
US6485926B2 (en) | 1999-12-22 | 2002-11-26 | Fuji Photo Film Co., Ltd. | Method for measuring protease activity |
US6515194B2 (en) | 1999-12-23 | 2003-02-04 | Ryan R. Neading | Diaper having centrally-located chromatographic layer with peripherally-located wetness indicator |
DE10009503A1 (en) | 2000-02-29 | 2001-08-30 | Roche Diagnostics Gmbh | Procedure for immobilizing conjugates in diagnostic tests |
US6607922B2 (en) | 2000-03-17 | 2003-08-19 | Quantum Design, Inc. | Immunochromatographic assay method and apparatus |
US20080050839A1 (en) * | 2000-03-21 | 2008-02-28 | Suslick Kenneth S | Apparatus and method for detecting lung cancer using exhaled breath |
CA2342683A1 (en) | 2000-04-03 | 2001-10-03 | Unilever Plc | Test methods and devices |
JP2001349892A (en) | 2000-04-03 | 2001-12-21 | Unilever Nv | Test method and device |
US6699722B2 (en) | 2000-04-14 | 2004-03-02 | A-Fem Medical Corporation | Positive detection lateral-flow apparatus and method for small and large analytes |
US6627459B1 (en) | 2000-04-19 | 2003-09-30 | Applied Biotech, Inc. | Immunoassay controls |
CU22968A1 (en) | 2000-06-07 | 2004-07-14 | Ct Ingenieria Genetica Biotech | PROCEDURE FOR THE DETECTION OF ANTI-TRANSGLUTAMINASE ANTIBODIES USED IN THE DIAGNOSIS OF CELIAC DISEASE |
US7052831B2 (en) | 2000-09-29 | 2006-05-30 | Becton Dickinson And Company | Detection of multiple analytes from a single sample using a multi-well, multi-analyte flow-through diagnostic test device |
JP2002122598A (en) * | 2000-10-16 | 2002-04-26 | Nitto Denko Corp | Test piece and expansion composition for immunoenzymo chromatography |
US6653149B1 (en) | 2000-10-16 | 2003-11-25 | Applied Biotech Inc. | Specimen collection device and method |
US6524864B2 (en) | 2000-12-28 | 2003-02-25 | Aurora L. Fernandez Decastro | Test strip for simultaneous detection of a plurality of analytes |
US6767710B2 (en) | 2001-03-30 | 2004-07-27 | Praxsys Biosystems, Llc | Prewetting stop flow test strip |
US6565808B2 (en) * | 2001-05-18 | 2003-05-20 | Acon Laboratories | Line test device and methods of use |
US6669908B2 (en) | 2001-07-25 | 2003-12-30 | Applied Biotech, Inc. | Urine test device |
US20030119203A1 (en) | 2001-12-24 | 2003-06-26 | Kimberly-Clark Worldwide, Inc. | Lateral flow assay devices and methods for conducting assays |
CA2471625A1 (en) | 2001-12-27 | 2003-07-24 | Inverness Medical Switzerland Gmbh | Novel device, system and method for fluorescence detection |
US7049150B2 (en) | 2001-12-28 | 2006-05-23 | Varian, Inc. | Binding assay device with non-absorbent carrier material |
AU2003240145A1 (en) | 2002-06-27 | 2004-01-19 | Unipath Limited | Assay reader |
US6875185B2 (en) | 2002-07-29 | 2005-04-05 | Branan Medical Corporation | Integrated confirmation sample in a body fluid test device and method of using |
US7314763B2 (en) | 2002-08-27 | 2008-01-01 | Kimberly-Clark Worldwide, Inc. | Fluidics-based assay devices |
US7285424B2 (en) | 2002-08-27 | 2007-10-23 | Kimberly-Clark Worldwide, Inc. | Membrane-based assay devices |
US7432105B2 (en) | 2002-08-27 | 2008-10-07 | Kimberly-Clark Worldwide, Inc. | Self-calibration system for a magnetic binding assay |
US7781172B2 (en) | 2003-11-21 | 2010-08-24 | Kimberly-Clark Worldwide, Inc. | Method for extending the dynamic detection range of assay devices |
US20040121334A1 (en) | 2002-12-19 | 2004-06-24 | Kimberly-Clark Worldwide, Inc. | Self-calibrated flow-through assay devices |
US7247500B2 (en) | 2002-12-19 | 2007-07-24 | Kimberly-Clark Worldwide, Inc. | Reduction of the hook effect in membrane-based assay devices |
US7459314B2 (en) | 2003-02-13 | 2008-12-02 | Inverness Medical Switzerland Gmbh | Lateral flow immunoassay controls |
US7297548B2 (en) * | 2003-03-28 | 2007-11-20 | Terumo Kabushiki Kaisha | Solid-phase saccharide sensing compounds |
EP1608665B1 (en) * | 2003-03-28 | 2018-04-25 | Terumo Kabushiki Kaisha | Solid-phase saccharide sensing compounds |
US20040197819A1 (en) | 2003-04-03 | 2004-10-07 | Kimberly-Clark Worldwide, Inc. | Assay devices that utilize hollow particles |
US7851209B2 (en) | 2003-04-03 | 2010-12-14 | Kimberly-Clark Worldwide, Inc. | Reduction of the hook effect in assay devices |
US7239394B2 (en) | 2003-06-04 | 2007-07-03 | Inverness Medical Switzerland Gmbh | Early determination of assay results |
US7315378B2 (en) | 2003-06-04 | 2008-01-01 | Inverness Medical Switzerland Gmbh | Optical arrangement for assay reading device |
JP2005056604A (en) | 2003-08-06 | 2005-03-03 | Hitachi Displays Ltd | Self-luminous flat display device |
JP4458327B2 (en) | 2003-08-28 | 2010-04-28 | キヤノン株式会社 | Method for quantifying target substance and probe carrier used in the method |
JP2007524844A (en) | 2003-09-22 | 2007-08-30 | ベクトン・ディキンソン・アンド・カンパニー | Quantification of biomolecular analytes by mass spectrometry using a dendrimer internal standard |
US7943395B2 (en) | 2003-11-21 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Extension of the dynamic detection range of assay devices |
US20050131287A1 (en) * | 2003-12-16 | 2005-06-16 | Kimberly-Clark Worldwide, Inc. | Detection of premature rupture of the amniotic membrane |
US20050191704A1 (en) | 2004-03-01 | 2005-09-01 | Kimberly-Clark Worldwide, Inc. | Assay devices utilizing chemichromic dyes |
US7524673B2 (en) * | 2004-05-10 | 2009-04-28 | 3M Innovative Properties Company | Biological soil detector |
US20060029976A1 (en) | 2004-08-06 | 2006-02-09 | Mcvicker Jerry K | Method for the detection of C-reactive protein in mammalian fluids |
US7662562B2 (en) | 2004-08-10 | 2010-02-16 | Becton, Dickinson And Company | Method for rapid identification of microorganisms |
JP2006119119A (en) * | 2004-09-24 | 2006-05-11 | Fuji Xerox Co Ltd | Polymer and ligand-immobilizing carrier |
US7629127B2 (en) | 2005-01-21 | 2009-12-08 | Dexall Biomedical Labs, Inc. | Method for the visual detection of specific antibodies by the use of lateral flow assays |
JP5144493B2 (en) | 2005-03-28 | 2013-02-13 | ベクトン・ディキンソン・アンド・カンパニー | Improved system and method for agitating suspended matter in liquid media |
US7939342B2 (en) | 2005-03-30 | 2011-05-10 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kits employing an internal calibration system |
US20060240569A1 (en) | 2005-04-20 | 2006-10-26 | Becton, Dickinson And Company | Semi-quantitative immunochromatographic device |
US7439079B2 (en) | 2005-04-29 | 2008-10-21 | Kimberly-Clark Worldwide, Inc. | Assay devices having detection capabilities within the hook effect region |
US7803319B2 (en) | 2005-04-29 | 2010-09-28 | Kimberly-Clark Worldwide, Inc. | Metering technique for lateral flow assay devices |
-
2006
- 2006-12-15 US US11/640,100 patent/US7935538B2/en not_active Expired - Fee Related
-
2007
- 2007-09-28 WO PCT/IB2007/053962 patent/WO2008075216A1/en active Application Filing
- 2007-09-28 JP JP2009540899A patent/JP5296703B2/en not_active Expired - Fee Related
- 2007-09-28 KR KR1020097012200A patent/KR101481189B1/en active IP Right Grant
- 2007-09-28 EP EP07826591.5A patent/EP2092332B1/en active Active
- 2007-09-28 CN CN2007800463124A patent/CN101558301B/en active Active
- 2007-09-28 CA CA002670526A patent/CA2670526A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4366241B1 (en) | 1980-08-07 | 1988-10-18 | ||
US5571684A (en) | 1994-11-07 | 1996-11-05 | Litmus Concepts, Inc. | Assay for proline iminopeptidase and other hydrolytic activities |
US6436651B1 (en) | 1997-12-16 | 2002-08-20 | Kimberly-Clark Worldwide, Inc. | Optical diffraction biosensor |
WO2001086302A1 (en) * | 2000-05-05 | 2001-11-15 | Pharmacia Diagnostics Ab | Assay device with timer function |
US6486227B2 (en) | 2000-06-19 | 2002-11-26 | Kimberly-Clark Worldwide, Inc. | Zinc-complex photoinitiators and applications therefor |
WO2003058246A1 (en) * | 2001-12-24 | 2003-07-17 | Kimberly-Clark Worldwide, Inc. | Flow-through assay with an internal calibration system using polyelectrolyte |
US6780896B2 (en) | 2002-12-20 | 2004-08-24 | Kimberly-Clark Worldwide, Inc. | Stabilized photoinitiators and applications thereof |
WO2005086744A2 (en) * | 2004-03-08 | 2005-09-22 | Metrika, Inc. | Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays |
WO2007027198A1 (en) * | 2005-08-31 | 2007-03-08 | Kimberly-Clark Worldwide, Inc. | Nitrite detection technique |
WO2007027234A2 (en) * | 2005-08-31 | 2007-03-08 | Kimberly-Clark Worldwide, Inc. | Enzyme detection technique |
WO2007027353A2 (en) * | 2005-08-31 | 2007-03-08 | Kimberly-Clark Worldwide, Inc. | Detection of proteases secreted from pathogenic microorganisms |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2217922A1 (en) * | 2007-12-14 | 2010-08-18 | Kimberly-Clark Worldwide, Inc. | Urine volume hydration test devices |
EP2217922A4 (en) * | 2007-12-14 | 2011-01-19 | Kimberly Clark Co | Urine volume hydration test devices |
US10900962B2 (en) | 2009-11-24 | 2021-01-26 | Sienna Cancer Diagnostics Inc. | Molecular nets and devices for capturing analytes including exosomes |
US9910040B2 (en) | 2012-07-09 | 2018-03-06 | Sevident, Inc. | Molecular nets comprising capture agents and linking agents |
US9733242B2 (en) | 2012-10-07 | 2017-08-15 | Sevident, Inc. | Devices for capturing analyte |
US9591290B2 (en) | 2014-06-10 | 2017-03-07 | Bitanimate, Inc. | Stereoscopic video generation |
Also Published As
Publication number | Publication date |
---|---|
EP2092332B1 (en) | 2014-01-15 |
US7935538B2 (en) | 2011-05-03 |
CA2670526A1 (en) | 2008-06-26 |
JP2010513857A (en) | 2010-04-30 |
KR20090100350A (en) | 2009-09-23 |
EP2092332A1 (en) | 2009-08-26 |
KR101481189B1 (en) | 2015-01-09 |
US20080145949A1 (en) | 2008-06-19 |
CN101558301A (en) | 2009-10-14 |
CN101558301B (en) | 2013-12-11 |
JP5296703B2 (en) | 2013-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2092332B1 (en) | Indicator immobilization on assay devices | |
EP1920251B1 (en) | Nitrite detection technique | |
US8044257B2 (en) | Absorbent article containing lateral flow assay device | |
US5945345A (en) | Device for preventing assay interference using silver or lead to remove the interferant | |
US7504235B2 (en) | Enzyme detection technique | |
US9103796B2 (en) | Multi-layered devices for analyte detection | |
ES2290524T3 (en) | CONTINUOUS FLOW TESTING DEVICES, SELF-CALIBRATION. | |
US7943395B2 (en) | Extension of the dynamic detection range of assay devices | |
US20070224689A1 (en) | Method for predicting or identifying the onset of premature membrane rupture during pregnancy | |
JPS63269056A (en) | Immunity testing apparatus | |
WO2005071413A1 (en) | Convenient detection method, detection apparatus and detection kit | |
US5231035A (en) | Latex agglutination assay | |
CN111033237B (en) | Sandwich assay for measuring analytes, including high concentrations of analytes, using decreasing signal portions of dose-response curves | |
JPWO2019124532A1 (en) | Immunochromatography equipment | |
CA1289471C (en) | Dry test strip for devices using oxygen demanding detection system | |
WO2005057216A1 (en) | Method of reducing the sensitivity of assay devices | |
JP2000065832A (en) | Filter type biological specific reaction measurement carrier and measurement using it | |
MXPA06005123A (en) | Method for extending the dynamic detection range of assay devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780046312.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07826591 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2670526 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009540899 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007826591 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097012200 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3411/CHENP/2009 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |